USA Financial Portformulas Corp acquired a new position in shares of Omeros Co. (NASDAQ:OMER) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,198 shares of the biopharmaceutical company’s stock, valued at approximately $451,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in shares of Omeros by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 391,649 shares of the biopharmaceutical company’s stock worth $7,609,000 after acquiring an additional 11,667 shares during the last quarter. Capital Analysts LLC increased its position in Omeros by 885.6% during the 4th quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock valued at $36,125,000 after purchasing an additional 530,899 shares during the period. Baird Financial Group Inc. increased its position in Omeros by 9.0% during the 4th quarter. Baird Financial Group Inc. now owns 62,296 shares of the biopharmaceutical company’s stock valued at $1,210,000 after purchasing an additional 5,151 shares during the period. Wedbush Securities Inc. increased its position in Omeros by 32.4% during the 4th quarter. Wedbush Securities Inc. now owns 94,923 shares of the biopharmaceutical company’s stock valued at $1,844,000 after purchasing an additional 23,241 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new stake in Omeros during the 4th quarter valued at approximately $973,000. 48.56% of the stock is owned by institutional investors and hedge funds.
Shares of Omeros Co. (OMER) traded up $0.11 on Wednesday, hitting $11.06. The stock had a trading volume of 643,219 shares, compared to its average volume of 1,360,000. The company has a market cap of $530.92, a P/E ratio of -9.37 and a beta of 3.57. Omeros Co. has a 12-month low of $8.36 and a 12-month high of $27.09. The company has a current ratio of 4.12, a quick ratio of 4.10 and a debt-to-equity ratio of -29.93.
Omeros (NASDAQ:OMER) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.03). The company had revenue of $13.76 million during the quarter, compared to the consensus estimate of $21.94 million. During the same period last year, the firm earned ($0.45) EPS. Omeros’s revenue was up 6.7% compared to the same quarter last year. equities research analysts expect that Omeros Co. will post -0.76 EPS for the current year.
Several analysts have recently commented on the stock. Needham & Company LLC downgraded shares of Omeros from a “buy” rating to a “hold” rating and set a $9.01 price objective for the company. in a research report on Friday, March 2nd. Maxim Group set a $24.00 target price on Omeros and gave the stock a “buy” rating in a report on Friday, March 2nd. HC Wainwright set a $30.00 target price on Omeros and gave the stock a “buy” rating in a report on Monday, March 5th. ValuEngine cut Omeros from a “sell” rating to a “strong sell” rating in a report on Friday, February 23rd. Finally, Cantor Fitzgerald set a $19.00 price objective on Omeros and gave the company a “hold” rating in a research note on Thursday, March 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $28.75.
COPYRIGHT VIOLATION NOTICE: “USA Financial Portformulas Corp Takes $451,000 Position in Omeros Co. (OMER)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/14/usa-financial-portformulas-corp-takes-451000-position-in-omeros-co-omer.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.